TEL AVIV, Israel, August 11, 2026
Teva Pharmaceutical Industries Ltd. announced that Moody’s Ratings has upgraded the company’s corporate credit rating to Baa3 from Ba1, moving Teva into investment-grade territory with a stable outlook. The upgrade represents a significant financial milestone for the global pharmaceutical company and reflects continued progress under its Pivot to Growth strategy. Moody’s cited Teva’s execution of its growth strategy, including the performance of key innovative products, expansion of its pharmaceutical pipeline, earnings growth, and continued debt reduction. The rating agency also highlighted Teva’s diversified revenue base, improving operating margins, strong free cash flow, and substantial cash position.
Moody’s Recognizes Teva’s Financial Progress
The move to an investment-grade Baa3 rating reflects Moody’s assessment that Teva has strengthened its financial profile while continuing to execute its long-term growth strategy. According to the rating agency, Teva’s progress has been supported by innovative medicines, an expanded product pipeline, earnings growth, and ongoing debt reduction. Moody’s also expects the company to continue reducing its debt over the next 12 to 18 months, indicating confidence in Teva’s ability to maintain financial discipline while investing in its business. The stable outlook accompanying the rating upgrade further reflects Moody’s current assessment of Teva’s financial position and operating trajectory. Teva’s improved credit standing is particularly significant given the company’s focus on transforming its business toward higher-value innovative medicines while maintaining its global generics operations. The company has been working to strengthen profitability, improve operational efficiency, and allocate resources toward areas with growth potential. The Moody’s upgrade provides external recognition of the progress achieved through this transformation, while potentially improving Teva’s financial flexibility as it continues to execute its strategic priorities.
Pivot to Growth Strategy Gains Momentum
Teva’s Pivot to Growth strategy is designed to transform the company into a leading innovative biopharmaceutical organization supported by its established global generics business. The company has been expanding its innovative medicines pipeline while continuing to develop and commercialize complex generic medicines and biosimilars. The strategy also includes efforts to improve the profitability and focus of its generics portfolio and strengthen the company’s overall financial performance. Moody’s recognition of Teva’s growing earnings, improving margins, and continued debt reduction suggests that these efforts are contributing to a stronger overall financial profile. The investment-grade upgrade follows a similar move by Fitch Ratings in May 2026, giving Teva further support from major credit-rating agencies. Teva said the combination of the ratings improvements strengthens its credit standing and supports potential eligibility for inclusion in leading fixed-income indices. Investment-grade status can also broaden the pool of institutional investors able to consider a company’s debt securities, potentially providing greater flexibility in future capital management.
Advertisement
Teva Gains Greater Financial Flexibility
For Teva, the upgraded credit rating comes as the company continues balancing investment in innovation with debt reduction and financial discipline. Improved access to capital and a stronger credit profile could provide additional flexibility as Teva advances its innovative medicines and biosimilar pipeline, manages its generics portfolio, and pursues opportunities to create long-term growth. The company said the rating upgrade reinforces its ability to continue investing in growth and innovation while maintaining a focus on financial stability. Teva’s transformation remains closely connected to its ability to develop and commercialize pharmaceutical products across neuroscience, immunology, generics, biosimilars, and other therapeutic areas. The Moody’s upgrade to investment grade marks an important milestone in Teva’s broader business transformation, reinforcing the company’s progress in reducing debt and strengthening its financial position. As Teva continues executing its Pivot to Growth strategy, the combination of an expanded innovative pipeline, diversified revenues, improving operating performance, and disciplined capital management will remain central to its efforts to build sustainable long-term value.
Source: Teva Pharmaceutical Industries press release
